We also anticipate that levels of hormones such as asprosin and BDNF may serve as early indicators and biomarkers for addressing risk factors associated with clinical conditions closely associated with BGN, such as eating disorders, anxiety disorders, and body dysmorphic disorders. This evidence concerns the gene BDNF and eating disorder.